ZFP36 Knockout cell line (HT-29)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZFP36 (ZFP36 zinc finger CCCH-type) encodes an RNA-binding regulatory protein that recognizes AU-rich regions in the 3′ untranslated regions of target mRNAs. It participates in regulation of gene expression and mRNA catabolism and responds to cytokine and epidermal growth factor signaling. Through sequence-specific RNA interactions, ZFP36 contributes to post-transcriptional control of gene expression and cellular responses to extracellular stimuli.

HT-29 is a human colorectal adenocarcinoma cell line established from a primary colon tumor of a 44-year-old female patient in 1964. The cells can undergo differentiation into mature goblet-like cells and produce mucin-secreting subclones, such as HT29-MTX, which exhibit characteristics of intestinal epithelial differentiation, including tight junction formation and mucus layer production. HT-29 is widely used as a model for studying colorectal cancer biology, intestinal epithelial differentiation, barrier function, and drug or nanoparticle transport.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.